europass Curriculum vitae

PERSONAL INFORMATION

Ivan Roberto Lolli

(+39) 080 4994277 (+39) 080 4994163

ivan.lolli@irccsdebellis.it

Sex Male | Date of birth 20/09/1953 | Nationality Italian

WORK EXPERIENCE

06/2010–Present — Medical Director
I.R.C.C.S "Saverio De Bellis"
Via Turi 27, 70013 Castellana Grotte (BA) (Italy)
https://www.sanita.puglia.it/web/debellis/

06/1996–08/2010 — Physician
University Hospital Policlinico Bari, Bari (Italy)
Oncology Dept.

1988–1996 — Physician
ASL BR6 Brindisi (Italy)
General Medicine Dept.

EDUCATION AND TRAINING

1985–1989 — Specialisation in Oncology
University of Bari, Bari (Italy)

01/1986–11/1986 — Fondation de France fellowship
Hôpital Saint-Louis, Paris (France)
Equipe Dr C. Dresch
Research Institute on Blood Diseases
Kinetics of cellular populations in Hematology and Oncology: cancer-therapeutic and therapeutic activities with various aspects of the management of cancer solid patients;
Primitive cerebral tumors and gastrointestinal stromal tumors (GIST).

1980–1984 — Specialization in Hematology
University of Bari, Bari (Italy)

1974–1980 — Degree in Medicine and Surgery
University of Perugia

PERSONAL SKILLS

Mother tongue(s) Italian

Foreign language(s)

	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken interaction	Spoken production	
English	B2	B2	B2	B2	B2
French	B2	B2	B2	B2	B2

Levels: A1 and A2: Basic user - B1 and B2: Independent user - C1 and C2: Proficient user
Common European Framework of Reference for Languages

ADDITIONAL INFORMATION

Digital skills: Good knowledge of MS Office package

Memberships: Italian Association of Medical Oncology

Clinical Research Experience

- **2018 -Observational Trial:**

Safety and Effectiveness of Ramucirumab in Patients with Advanced Gastric Cancer in the European Union and North America: A Prospective Observational Registry (I4T-MC-JVDD)

Sponsor: Eli Lilly and Company

2018 - Observational Trial:

Quality of life, compliance, safety and effectiveness in fit older metastatic colorectal patients with cancer treated in first-line with chemotherapy plus cetuximab. A retrospective analysis from the Observer study."

Sponsor: Merck Serono

- **2018 - Phase II Interventional Trial**

Maintenance therapy with Trabectedin after combination therapy Liposomal Doxorubicin plus Trabectedin vs Liposomal Doxorubicin plus Trabectedin in patients affected by relapsed ovarian cancer recurring between 6 and 12 months after platinum based chemotherapy'.

Sponsor: Azienda Ospedaliera per l' Emergenza Cannizzaro di Catania

- **2018 - Phase II Interventional Trial**

Intermittent or continuous Panitumumab plus FOLFIRI for first line treatment of patients with RAS and BRAF wild-type metastatic colorectal cancer: a randomized phase 2 trial (IMPROVE)

Sponsor: Istituto Nazionale dei Tumori, Fondazione "G. Pascale" Napoli.

- **2017 - Phase II Interventional Trial**:

A Randomized Phase II Trial of Capecitabine and Temozolomide (CAPTEM) or FOLFIRI as SEcond-line Therapy in NEuroendocrine CArcinomas and Exploratory Analysis of Predictive Role of Positron Emission Tomography (PET) Imaging and Biological Markers" (SENECA).

Sponsor: Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori (IRST) Meldola

- **2017** - Prospective multicenter **observational study** on the quality of Life of mCRC RAS wt patients receiving Anti-EGFR MAbs + Folfox or Folfiri as first line of treatment (SILQ).
Sponsor: Amgen

- **2016 - Observational Study** on quality of life, safety and effectiveness of first-line cetuximab plus chemotherapy in KRAS wild-type metastatic colorectal cancer patients: the ObservEr Study.

Sponsor: Merck Serono

Certifications

13/09/2018 - ICH-GCP Training Certificate
National Institute of Gastroenterology "S. De Bellis" Castellana Grotte (BA)

Trainer: Dr. Stefano Lagravinese
Topics:

- GCP and History
- Definitions
- Clinical Research Actors
- Investigator Qualifications
- IDB
- Research Protocol
- Delegation of Responsability
- Informed Consent Process
- Adverse Events
- Source Document and CRF Management
- SDV

11/06/2018 - Clinical Research, Phase I Clinical Trials and SOP
National Institute of Gastroenterology "S. De Bellis" Castellana Grotte (BA)
Trainer: Dr. Stefano Lagravinese
Topics:

- Methodology of clinical research;
- GoodClinicalPractice;
- Informed consent;
- Source Document Management;
- Phase 1 studies;
- Standard Operating Procedures of the URCF1.

In compliance with the Italian legislative Decree n°196 of 30/06/2003 and art. 13 GDPR (EU General Data Protection Regulation n° 2016/679), I hereby authorize you to use and process my personal details contained in this document.

Date 21/01/22 Signature